Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib with CTC Monitoring in Advanced Solid Tumors
NCT04239443Phase 2Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- Jan 2019
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in non-small cell lung cancer (NSCLC), soft tissue sarcoma (STS), uterine cancer, Cervical Cancer (CC), endometrial cancer (EC), sponsored by Hunan Cancer Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)soft tissue sarcoma (STS)uterine cancerCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04239443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239443.